About rallybio corp - RLYB
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.
RLYB At a Glance
Rallybio Corp.
234 Church Street
New Haven, Connecticut 06510
| Phone | 1-203-859-3820 | Revenue | 858.00K | |
| Industry | Biotechnology | Net Income | -8,978,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 34.906% | |
| Fiscal Year-end | 12 / 2026 | Employees | 14 | |
| View SEC Filings |
RLYB Valuation
| P/E Current | 2.167 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 36.012 |
| Price to Book Ratio | 0.50 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.846 |
| Enterprise Value to Sales | -27.578 |
| Total Debt to Enterprise Value | -0.007 |
RLYB Efficiency
| Revenue/Employee | 61,285.714 |
| Income Per Employee | -641,285.714 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.013 |
RLYB Liquidity
| Current Ratio | 14.505 |
| Quick Ratio | 14.505 |
| Cash Ratio | 12.961 |
RLYB Profitability
| Gross Margin | 89.277 |
| Operating Margin | -3,270.862 |
| Pretax Margin | -944.522 |
| Net Margin | -1,046.387 |
| Return on Assets | -13.773 |
| Return on Equity | -15.012 |
| Return on Total Capital | -15.444 |
| Return on Invested Capital | -15.002 |
RLYB Capital Structure
| Total Debt to Total Equity | 0.304 |
| Total Debt to Total Capital | 0.303 |
| Total Debt to Total Assets | 0.283 |
| Long-Term Debt to Equity | 0.141 |
| Long-Term Debt to Total Capital | 0.141 |